Aurobindo Pharma News and Updates

Name: Latest research reports of Aurobindo Pharma Ltd. authored by Deven Choksey and published by - Trendlyne research reports.
Item: Aurobindo Pharma Ltd.
Rating: 4
Author: Deven Choksey

Keep track of all breaking news on Aurobindo Pharma from all sources in a single place.

Aurobindo Pharma Ltd.

03 Oct 2026

1693.00

2.92%

Aurobindo Pharma: Strong dose of growth opportunities

Business Line

With key projects moving into commercial production, the drugmaker has stronger near-term growth visibility and also a long runway

Aurobindo Pharma Ltd. has an average target of 1540.75 from 8 brokers.

Aurobindo Pharma Ltd.

30 Sep 2026

1693.00

2.92%

Aurobindo Pharma's Acrotech enters US dermatology market with Adquey launch

Business Standard

To support the launch and expand this therapeutic segment, the company has set up a dedicated dermatology business unit, the filing said.

Aurobindo Pharma Ltd.'s price crossed above 30Day SMA today

Aurobindo Pharma Ltd.

22 Sep 2026

1693.00

2.92%

Multiple growth triggers ahead for Aurobindo Pharma as outlook stays strong

Business Standard

Respiratory launches, CDMO expansion and strong US and European businesses are key growth drivers; the stock trades at just under 16 times estimated FY28 earnings

Promoters unpledged 9.90% of shares in last quarter. Total pledge stands at 13.75% of promoter holdings

Aurobindo Pharma Ltd.

15 Sep 2026

1693.00

2.92%

Aurobindo Pharma gets USFDA approval for generic inhalation aerosol for asthma patients

Business Line

The approval is Aurobindo's first metered-dose inhaler (MDI), marking a milestone in its expansion into complex respiratory therapies

Aurobindo Pharma Ltd. has an average target of 1540.75 from 8 brokers.

Aurobindo Pharma Ltd.

31 Aug 2026

1693.00

2.92%

Aurobindo Pharma enters US inhalation market with generic Advair launch

Business Standard

The launch marks Aurobindo Pharma's entry into the US inhalation market and expands its complex generics portfolio beyond conventional oral solid formulations

Aurobindo Pharma Ltd. is trading above all available SMAs

Aurobindo Pharma Ltd.

14 Aug 2026

1693.00

2.92%

USFDA issues warning letter to Aurobindo Pharma's Telangana facility

Business Standard

Aurobindo Pharma on Friday said the US health regulator has issued a warning letter to a formulation manufacturing facility of its arm, Eugia Pharma Specialities Ltd, in Telangana. In May this year the company had stated that the US Food and Drug Administration (USFDA) inspected Unit-I, a formulation manufacturing facility of Eugia Pharma Specialities Ltd located at Telangana from February 16 to February 27, 2026. The inspection had concluded with four observations and the USFDA had determined the facility as 'official action indicated' (OAI). "Subsequent to OAI, the unit has received a warning letter," Aurobindo Pharma said in a regulatory filing. There is no impact on the existing supplies to the US markets, it added. The company further said the Unit I of Eugia Pharma Specialities Ltd, is contributing to about 2 per cent to company's overall group revenue. Aurobindo Pharma said it remains committed to working closely with the US FDA and continues to enhance its compliance on a

Aurobindo Pharma Ltd. is trading above all available SMAs

Aurobindo Pharma arm Eugia Pharma's Telangana unit gets warning letter from USFDA

Business Line | 14 Aug 2026

Aurobindo Pharma Ltd.

07 Aug 2026

1693.00

2.92%

Outlook

Accumulate: Aurobindo Pharma Ltd.

Target

Deven Choksey

Aurobindo Pharma is well positioned to deliver sustainable double-digit growth, supported by healthy momentum across its US, Europe, India, and Growth Markets businesses, along with a steady cadence of complex product launches.

Aurobindo Pharma Ltd.'s price crossed above 50Day SMA today

Aurobindo Pharma Ltd.

06 Aug 2026

1693.00

2.92%

to see Rapid results content

Aurobindo Pharma Ltd.

06 Aug 2026

1693.00

2.92%

Operational delivery remains on track

Buy: Aurobindo Pharma Ltd.

Target

Motilal Oswal

Aurobindo Pharma (ARBP) delivered in-line revenue in 1QFY27. It delivered better-than-expected EBITDA/PAT (6%/8% beat) for the quarter.

Promoters unpledged 9.90% of shares in last quarter. Total pledge stands at 13.75% of promoter holdings

Aurobindo Pharma Ltd.

05 Aug 2026

1693.00

2.92%

Aurobindo Pharma posts record Q1 revenue of 9,150 crore; PAT up 25%

Business Line

Broad-based growth across business segments helped the drugmaker deliver record quarterly sales and stronger profitability despite a dynamic global operating environment